|
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
RECRUITINGPhase 2Sponsored by Vertex Pharmaceuticals Incorporated
Actively Recruiting
PhasePhase 2
SponsorVertex Pharmaceuticals Incorporated
Started2026-05-13
Est. completion2029-03-02
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
Locations15 sites
View on ClinicalTrials.gov →
NCT07501702
Summary
The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).
Eligibility
Age: 18 Years – 80 YearsHealthy volunteers accepted
Key Inclusion Criteria: * Age 18-80 years * Diagnosis of generalized myasthenia gravis with generalized muscle weakness and fitting MGFA clinical classification II-IV * Additional inclusion criteria are defined in the protocol Key Exclusion Criteria: * History of thymic surgery within 6 months of screening * History of malignancy within the last 5 years * Additional exclusion criteria are defined in the protocol Other protocol defined Inclusion/Exclusion criteria will apply.
Conditions2
CancerMyasthenia Gravis, Generalized
Interventions1
Locations15 sites
Tri Valley Neurology Medical Associates Inc.
Neurology Offices
SFM Clinical Reseach, LLC
Homestead Associates in Research
UF Health Jacksonville Respiratory Therapy (PFT and DLCO)
Find trials near these locations
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2
SponsorVertex Pharmaceuticals Incorporated
Started2026-05-13
Est. completion2029-03-02
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
Locations15 sites
View on ClinicalTrials.gov →
NCT07501702